Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death

Cell Immunol. 2002 Dec;220(2):96-106. doi: 10.1016/s0008-8749(03)00031-5.

Abstract

Iron is an essential element for the neoplastic cell growth, and iron chelators have been tested for their potential anti-proliferative and cytotoxic effects. To determine the mechanism of cell death induced by iron chelators, we explored the pathways of the three structurally related mitogen-activated protein (MAP) kinase subfamilies during apoptosis induced by iron chelators. We report that the chelator deferoxamine (DFO) strongly activates both p38 MAP kinase and extracellular signal-regulated kinase (ERK) at an early stage of incubation, but slightly activates c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) at a late stage of incubation. Among three MAP kinase blockers used, however, the selective p38 MAP kinase inhibitor SB203580 could only protect HL-60 cells from chelator-induced cell death, indicating that p38 MAP kinase serves as a major mediator of apoptosis induced by iron chelator. DFO also caused release of cytochrome c from mitochondria and induced activation of caspase 3 and caspase 8. Interestingly, treatment of HL-60 cells with SB203580 greatly abolished cytochrome c release, and activation of caspase 3 and caspase 8. Collectively, the current study reveals that p38 MAP kinase plays an important role in iron chelator-mediated cell death of HL-60 cells by activating downstream apoptotic cascade that executes cell death pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Apoptosis / physiology*
  • Caspase 3
  • Caspase 8
  • Caspase 9
  • Caspases / metabolism
  • Cytochrome c Group / metabolism
  • Deferoxamine / antagonists & inhibitors
  • Deferoxamine / pharmacology*
  • Enzyme Activation
  • Enzyme Inhibitors / pharmacology
  • HL-60 Cells
  • Humans
  • Imidazoles / pharmacology
  • Intracellular Membranes / drug effects
  • Intracellular Membranes / physiology
  • Iron / antagonists & inhibitors
  • Iron / metabolism*
  • Iron Chelating Agents / pharmacology*
  • Jurkat Cells / enzymology
  • Jurkat Cells / metabolism
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Mice
  • Mitochondria / drug effects
  • Mitochondria / physiology
  • Mitogen-Activated Protein Kinases / metabolism*
  • Pyridines / pharmacology
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Cytochrome c Group
  • Enzyme Inhibitors
  • Imidazoles
  • Iron Chelating Agents
  • Pyridines
  • Iron
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • CASP3 protein, human
  • CASP8 protein, human
  • CASP9 protein, human
  • Casp3 protein, mouse
  • Casp8 protein, mouse
  • Casp9 protein, mouse
  • Caspase 3
  • Caspase 8
  • Caspase 9
  • Caspases
  • Deferoxamine
  • SB 203580